Bristol-Myers (BMY), Pfizer (PFE) Receive Approval for ELIQUIS in Japan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ELIQUIS Receives FDA Approval in Reducing Certain Risks in Nonvalvular Atrial Fibrillation
January 2, 2013 8:03 AM ESTBristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) approved ELIQUIS® (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Atrial fibrillation, the most common type of irregular heartbeat, affects approximately 5.8 million people in the U.S., and results in a five times greater risk of stroke. In the U.S., 15 percent of strokes are attributable to atrial fibrillation.
The approval of ELIQUIS offers patients with nonvalvular atrial fibrillation a... More
Pfizer (PFE) and Bristol-Meyers (BMY) win FDA approval for Eliquis
December 28, 2012 4:14 PM ESTPfizer, Inc. (NYSE: PFE) and Bristol-Meyers (NYSE: BMY) win FDA approval for Eliquis, according to Bloomberg headlines.... More
